Pituitary Tumors

Clinical Radiation Oncology: Third Edition

Volumn , Issue , 2012, Pages 493-509

  Suh, John H ^a   Chao, Sam T ^a   Weil, Robert J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876895055     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1637-5.00027-4     Document Type: Chapter

References (216)

1. Tada M, Kobayashi H, Moriuchi T Molecular basis of pituitary oncogenesis. Neuro-Oncology 1999, 45:83-96.
2. Asa SL, Ezzat S The pathogenesis of pituitary tumors. Annu Rev Pathol 2009, 4:97-126.
3. Elston MS, McDonald KL, Clifton-Bligh RJ, Robinson BG Familial pituitary tumor syndromes. Nat Rev Endocrinol 2009, 5:453-461.
4. Bates AS, Farrell WE, Bicknell EJ, et al. Allelic deletion in pituitary adenomas reflects aggressive biologic activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 1997, 82:818-824.
5. Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A 2001, 98:1118-1123.
6. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000, 26:89-92.
7. Georgitsi M, Raitila A, Karhu A, et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci U S A 2007, 104:4101-4105.
8. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
9. Daly AF, Rixhon M, Adams C, et al. High prevalence of pituitary adenomas. A cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006, 91:4769-4775.
10. Fernandez A, Karavitaki N, Wass JA Prevalence of pituitary adenomas. A community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010, 72:377-382.
11. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas. A systematic review. Cancer 2004, 101:613-619.
12. Spada A, Lania A, Mantovani G Hormonal signaling and pituitary adenomas. Neuroendocrinology 2007, 85:101-109.
13. Xu M, Shorts-Cary L, Knox AJ, et al. Epidermal growth factor receptor pathway substrate 8 (eps8) is overexpressed in human pituitary tumors. Role in proliferation and survival. Endocrinology 2009, 150:2064-2071.
14. Chesnokova V, Zonis S, Kovacs K, et al. p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A 2008, 105:17498-17503.
15. Hayward BE, Barlier A, Korbonits M, et al. Imprinting of the G(s) α gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001, 107:R31-R36.
16. Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999, 84:761-767.
17. Ezzat S, Zheng L, Zhu XF, et al. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002, 109:69-78.
18. Asa SL, Kovacs K, Shlomad S The hypothalamic-pituitary axis. The pituitary 1995, p 3. Blackwell Scientific, Cambridge. S. Melmed (Ed.).
19. Hardy J Transsphenoidal surgery of hypersecreting pituitary tumors. Diagnosis and treatment of pituitary tumors 1973, 179. Elsevier, New York. P.O. Kohler, F.T. Ross (Eds.).
20. Teramoto A, Hirakawa K, Sanno N, et al. Incidental pituitary lesions in 1000 unselected autopsy specimens. Radiology 1994, 193:161-164.
21. Bonneville JF, Bonneville F, Cattin F Magnetic resonance imaging of pituitary adenomas. Eur Radiol 2005, 15:543-548.
22. Lloyd RJ, Kovacs K, Young WF, et al. Tumours of the pituitary gland. Pathology and genetics of tumours of endocrine organs 2004, 9-48. International Agency for Research and Cancer (IARC), Lyon, France. R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng (Eds.).
23. Branch CL, Laws ER Metastatic tumors of the sella turcica masquerading as primary pituitary tumors. J Clin Endocrinol Metab 1987, 65:469-474.
24. Pernicone PJ, Scheithauer BW Invasive pituitary adenoma and pituitary carcinoma. Diagnosis and management of pituitary tumors. totowa 2001, 369-386. Humana Press, New Jersey. K. Thapar, K. Kovacs, B.W. Scheithauer, R.V. Lloyd (Eds.).
25. Saeger W, Lüdecke B, Lüdecke DK Comparison of proliferation markers and clinical tumor growth in inactive adenomas. Endocr Pathol 2004, 15:264-265.
26. Amar AP, Hinton DR, Krieger MD, Weiss MH Invasive pituitary adenomas. Significance of proliferation parameters. Pituitary 1999, 2:117-122.
27. Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003, 63:2251-2255.
28. Asa SL, Ezzat S The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998, 19:798-827.
29. Asa SL, Ezzat S Molecular basis of pituitary development and cytogenesis. Front Horm Res 2004, 32:1-19.
30. Zhu X, Gleiberman AS, Rosenfeld MG Molecular physiology of pituitary development. Signaling and transcriptional networks. Physiol Rev 2007, 87:933-963.
31. Loh JA, Verbalis JG Disorders of water and salt metabolism associated with pituitary disease. Endocrinol Metab Clin North Am 2008, 37:213-234.
32. Gopan T, Toms SA, Prayson RA, et al. Symptomatic pituitary metastases from renal cell carcinoma. Pituitary 2007, 10:251-259.
33. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome. An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008, 93:1526-1540.
34. Klibanski A Clinical practice. Prolactinomas. N Engl J Med 2010, 362:1219-1226.
35. Melmed S Medical progress. Acromegaly. N Engl J Med 2006, 355:2558-2573.
36. Levivier M, Massager N, Wikler D, et al. Integration of functional imaging in radiosurgery. The example of PET scan. Prog Neurol Surg 2007, 20:68-81.
37. Bakiri F, Tatai S, Aouali R, et al. Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery. Prognosis factors and long-term follow-up. J Endocrinol Invest 1996, 19:572-580.
38. Esposito F, Dusick JR, Cohan P, et al. Clinical review. Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 2006, 91:7-13.
39. Hardy J, Verzina JL Transsphenoidal neurosurgery of intracranial neoplasm. Advances in neurology 1976, 261. Raven Press, New York, (updated at the International Pituitary Conference, Zurich, 1987). R.A. Thompson, J.R. Green (Eds.).
40. Wilson CB Neurosurgical management of large and invasive pituitary tumors. Clinical management of pituitary disorders 1979, 335. Raven Press, New York. G.T. Tinadall, W.F. Collins (Eds.).
41. Laws ER, Jane JA Neurosurgical approach to treating pituitary adenomas. Growth Horm IGF Res 2005, 15(Suppl A):S36-S41.
42. Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas. Diagnosis and management in 43 patients. Eur J Endocrinol 2003, 148:433-442.
43. Benveniste RJ, King WA, Walsh J, et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 2005, 102:1004-1012.
44. White DR, Sonnenburg RE, Ewend MG, et al. Safety of minimally invasive pituitary surgery (MIPS) compared with a traditional approach. Laryngoscope 2004, 114:1945-1948.
45. Atkinson AB, Kennedy A, Wiggman MI, et al. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 2005, 63:549-559.
46. Ciric I, Ragin A, Baumgartner C, Pierce D Complications of transsphenoidal surgery. Results of the national survey, review of the literature, and personal experience. Neurosurgery 1997, 40:225-237.
47. Nemergut EC, Zuo Z, Jane JA, et al. Predictors of diabetes insipidus after transsphenoidal surgery. A review of 881 patients. J Neurosurg 2005, 103:448-454.
48. Barker FG, Klibanski A, Swearingen B Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000. Mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003, 88:4709-4719.
49. Stewart PM Pegvisomant. An advance in clinical efficacy in acromegaly. Eur J Endocrinol 2003, 148(Suppl 2):S27-S32.
50. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev 2010, 31:301-342.
51. Jalali R, Brada M Radiosurgery for pituitary adenoma. Crit Rev Neurosurg 1999, 9:167-173.
52. Laws ER, Sheehan JP, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas. A review of the literature. J Neurooncol 2004, 69:257-272.
53. Minniti G, Gilbert DC, Brada M Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord 2009, 10:135-144.
54. Mackley HB, Reddy CA, Lee SY, et al. Intensity-modulated radiotherapy for pituitary adenomas. The preliminary report of the Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 67:232-239.
55. Kumar S, Burke K, Nalder C, et al. Treatment accuracy of fractionated stereotactic radiotherapy. Radiother Oncol 2005, 74:53-59.
56. Stafford SL, Pollock BE, Leavitt JA, et al. A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2003, 55:1177-1181.
57. Tishler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves in the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993, 27:215-221.
58. Jagannathan J, Sheehan JP, Pouratian N, et al. Gamma Knife surgery for Cushing's disease. Neurosurgery 2007, 106:980-987.
59. Snyder PJ Clinically nonfunctioning pituitary adenomas. Endocrinol Metab Clin North Am 1993, 22:163-175.
60. Wang H, Sun W, Fu Z, et al. The pattern of visual impairment in patients with pituitary adenoma. J Int Med Res 2008, 36:1064-1069.
61. Turner HE, Stratton IM, Byrne JV, et al. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation. A follow-up study. Clin Endocrinol (Oxf) 1999, 51:281-284.
62. Dekkers OM, Pereira AM, Roelfsema F, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006, 91:1796-1801.
63. Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD Radiosurgery for residual or recurrent nonfunctioning pituitary adenoma. J Neurosurg 2002, 97(5 Suppl):408-414.
64. Petrovich Z, Yu C, Giannotta SL, Apuzzo ML Gamma knife radiosurgery for pituitary adenoma. Early results. Neurosurgery 2003, 53:51-59.
65. Losa M, Valle M, Mortini P, et al. Gamma knife surgery for treatment of residual nonfunctioning pituitary adenomas after surgical debulking. J Neurosurg 2004, 100(3):438-444.
66. Iwai Y, Yamanaka K, Yoshioka K Radiosurgery for nonfunctioning pituitary adenomas. Neurosurgery 2005, 56(4):699-705.
67. Mingione V, Yen CP, Vance ML, et al. Gamma surgery in the treatment of nonsecretory pituitary macroadenoma. J Neurosurg 2006, 104(6):876-883.
68. Liscak R, Vladyka V, Marek J, et al. Gamma knife radiosurgery for endocrine-inactive pituitary adenomas. Acta Neurochir (Wien) 2007, 149(10):999-1006.
69. Pollock BE, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas. Results from a 15-year experience. Int J Radiat Oncol Biol Phys 2008, 70:1325-1329.
70. Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993, 38:571-578.
71. Sasaki R, Murakami M, Okamoto Y, et al. The efficacy of conventional radiation therapy in the management of pituitary adenomas. Int J Radiat Oncol Biol Phys 2000, 47:1337-1345.
72. Naidich MJ, Russell EJ Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 1999, 28:45-79.
73. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev 2006, 27:485-534.
74. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994, 331:904-909.
75. Valassi E, Klibanski A, Biller BM Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010, 95:1025-1033.
76. Sheline G, Grossman A, Jones AE, et al. Radiation Therapy for Prolactinomas 1984, Raven Press, New York.
77. Littley MD, Shalet SM, Reid H, et al. The effect of external pituitary irradiation on elevated serum prolactin levels in patients with pituitary macroadenomas. Q J Med 1991, 81:985-998.
78. Tsagarakis S, Grossman A, Plowman PN, et al. Megavoltage pituitary irradiation in the management of prolactinomas. Long-term follow-up. Clin Endocrinol 1991, 34:399-406.
79. Landolt AM, Lomax N Gamma Knife radiosurgery for prolactinomas. J Neurosurg 2000, 93(Suppl 3):14-18.
80. Pan L, Zhang N, Wang EM, et al. Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg 2000, 93(Suppl 3):10-13.
81. Choi JY, Chang JH, Chang JW, et al. Radiological and hormonal responses of functioning pituitary adenomas after gamma knife radiosurgery. Yonsei Med J 2003, 44:602-607.
82. Pouratian N, Sheehan J, Jagannathan J, et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 2006, 59:255-266.
83. Ježková J, Hána V, Kršek M, et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf) 2009, 70:732-741.
84. Pollock BE, Brown PD, Nippoldt TB, Young WF Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas. Neurosurgery 2008, 62:1271-1278.
85. Castinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 2009, 94:3400-3407.
86. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management. An update. J Clin Endocrinol Metab 2009, 94:1509-1517.
87. Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acromegaly with apparently normal GH secretion. Implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002, 87:3537-3542.
88. Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010, 95:3141-3148.
89. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement. Medical management of acromegaly. Eur J Endocrinol 2005, 153:737-740.
90. Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83:3419-3426.
91. Erturk E, Tuncel E, Kiyici S, et al. Outcome of surgery for acromegaly performed by different surgeons. Importance of surgical experience. Pituitary 2005, 8:93-97.
92. Freda PU, Wardlaw SL, Post KD Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998, 89:353-358.
93. Biermasz NR, van Dulen H, Roelfsema F Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000, 85:4596-4602.
94. Krieger MD, Couldwell WT, Weiss MH Assessment of long-term remission of acromegaly after surgery. J Neurosurg 2003, 98:719-724.
95. Kreutzer J, Vance ML, Lopes MBS, Laws ER Surgical management of GH-secreting pituitary adenomas. An outcome study using modern remission criteria. J Clin Endocrinol Metab 2001, 86:4072-4077.
96. Nomikos P, Buchfelder M, Fahlbusch R The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical cure. Eur J Endocrinol 2005, 152:379-387.
97. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly. An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002, 87:4554-4563.
98. Freda PU Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002, 87:3013-3018.
99. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005, 90:4405-4410.
100. Bhayana S, Booth GL, Asa SL, et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005, 90:6290-6295.
101. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342:1171-1177.
102. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358:1754-1759.
103. Eastman RC, Gorden P, Glatstein E, Roth J Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992, 21:693-712.
104. Bates AS, Van't Hoff W, Jones JM, Clayton RN An audit of outcomes of treatment in acromegaly. Q J Med 1993, 86:293-299.
105. Zhang N, Pan L, Wang EM, et al. Radiosurgery for growth hormone-producing pituitary adenomas. J Neurosurg 2000, 93(Suppl 3):6-9.
106. Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly. Long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000, 85:3779-3785.
107. Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005, 62:210-216.
108. Jenkins PJ, Bates P, Carson MN, et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006, 91:1239-1245.
109. Jallad RS, Musolino NR, Salgado LR, et al. Treatment of acromegaly. Is there still a place for radiotherapy?. Pituitary 2007, 10:53-59.
110. Jaffe CA Reevaluation of conventional pituitary irradiation in the therapy of acromegaly. Pituitary 1999, 2:55-62.
111. Jezkova J, Marek J, Hana V, et al. Gamma knife radiosurgery for acromegaly. Long-term experience. Clin Endocrinol (Oxf) 2006, 64:588-595.
112. Pollock BE, Jacob JT, Brown PD, et al. Radiosurgery of growth hormone-producing pituitary adenomas. Factors associated with biochemical remission. J Neurosurg 2007, 106:833-838.
113. Vik-Mo EO, Oksnes M, Pedersen PH, et al. Gamma knife stereotactic radiosurgery for acromegaly. Eur J Endocrinol 2007, 157:255-263.
114. Losa M, Gioia L, Picozzi P, et al. The role of stereotactic radiotherapy in patients with growth hormone secreting pituitary adenoma. J Clin Endocrinol Metab 2008, 93:2546-2552.
115. Jagannathan J, Pouratian N, Laws ER, et al. Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery. Neurosurgery 2008, 62:1262-1270.
116. Ronchi CL, Attanasio R, Verrua E, et al. Efficacy and tolerability of gamma knife radiosurgery in acromegaly. A 10-year follow-up study. Clin Endocrinol (Oxf) 2009, 71:846-852.
117. Castinetti F, Morange I, Dufour H, et al. Radiotherapy and radiosurgery in acromegaly. Pituitary 2009, 12:3-10.
118. Landolt AM, Haller D, Lomax N, et al. Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metabol 2000, 85:1287-1289.
119. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome. A consensus statement. J Clin Endocrinol Metab 2008, 93:2454-2462.
120. Nieman LK Medical therapy of Cushing's disease. Pituitary 2002, 5:77-82.
121. Weiss MH, Couldwell WT Gamma knife radiosurgery for Cushing's disease. J Neurosurg 2007, 106:976-977.
122. Bochicchio D, Losa M, Buchfelder M Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery. A retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 1995, 80:3114-3120.
123. Pouratian N, Prevedello DM, Jagannathan J, et al. Outcomes and management of patients with Cushing's disease without pathological confirmation of tumor resection after transsphenoidal surgery. J Clin Endocrinol Metab 2007, 92:3383-3388.
124. Cavagnini F, Pecori Giraldi F Epidemiology and follow-up of Cushing's disease. Ann Endocrinol (Paris) 2001, 62:168-172.
125. Flitsch J, Knappe UJ, Ludecke DK The use of postoperative ACTH levels as a marker for successful transsphenoidal microsurgery in Cushing's disease. Zentralbl Neurochir 2003, 64:6-11.
126. Patil CG, Prevedello DM, Lad SP, et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 2008, 93:358-362.
127. Schteingart DE Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs 2009, 14:661-671.
128. Devoe DJ, Miller WL, Conte FA, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997, 82:3196-3202.
129. Jennings AS, Liddle GW, Orth DN Results of treating childhood Cushing's disease with pituitary irradiation. N Engl J Med 1977, 297:957-962.
130. Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997, 336:215-217.
131. Minniti G, Osti M, Jaffrain-Rea ML, et al. Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neurooncol 2007, 84:79-84.
132. Littley MD, Shalet SM, Beardwell CG, et al. Long-term follow-up of low-dose external pituitary irradiation for Cushing's disease. Clin Endocrinol (Oxf) 1990, 33:445-455.
133. Tsang RW, Brierley JD, Panzarella T, et al. Radiation therapy for pituitary adenoma. Treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys 1994, 30:557-565.
134. Höybye C, Grenbäck E, Rähn T, et al. Adrenocorticotropic hormone producing pituitary tumors:12-to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 2001, 49:284-292.
135. Kobayashi T, Kida Y, Mori Y Gamma knife radiosurgery in the treatment of Cushing disease. Long-term results. J Neurosurg 2002, 97(Suppl. 5):422-428.
136. Nelson DH, Meakin JW, Thorn GW ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome. Ann Intern Med 1960, 52:560-569.
137. Mauermann WJ, Sheehan JP, Chernavvsky DR, et al. Gamma Knife surgery for adrenocorticotropic hormone-producing pituitary adenomas after bilateral adrenalectomy. J Neurosurg 2007, 106:988-993.
138. Pollock BE, Young WF Stereotactic radiosurgery for patients with ACTH-producing pituitary adenomas after prior adrenalectomy. Int J Radiat Oncol Biol Phys 2002, 54:839-841.
139. Clarke MJ, Erickson D, Castro R, et al. Thyroid-stimulating hormone pituitary adenomas. J Neurosurg 2008, 109:17-22.
140. Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996, 17:610-638.
141. Pernicone PJ, Scheithauer BW, Sebo TJ, et al. Pituitary carcinoma. A clinicopathologic study of 15 cases. Cancer 1997, 79:804-812.
142. Fadul CE, Kominsky AL, Meyer LP, et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 2006, 105:621-626.
143. Schoenthaler R, Albright NA, Wara WM, et al. Re-irradiation of pituitary adenoma. Int J Radiat Oncol Biol Phys 1992, 24:307-314.
144. Flickinger JC, Deutsch M, Lunsford LD Repeat megavoltage irradiation of pituitary and suprasellar tumors. Int J Radiat Oncol Biol Phys 1989, 17:171-175.
145. Fassett DR, Couldwell WT Metastases to the pituitary gland. Neurosurg Focus 2004, 16:E8.
146. Kano H, Niranjan A, Kondziolka D, et al. Stereotactic radiosurgery for pituitary metastases. Surg Neurol 2009, 72:248-255.
147. Sohn JW, Dalzell JG, Suh JH, et al. Dose-volume histogram analysis of techniques for irradiating pituitary adenomas. Int J Radiat Oncol Biol Phys 1995, 32:831-837.
148. Perks JR, Jalali R, Cosgrove VP, et al. Optimization of stereotactically guided conformal treatment planning of sellar and parasellar tumors, based on normal brain dose volume histograms. Int J Radiat Oncol Biol Phys 1999, 45:507-513.
149. Voges J, Kocher M, Runge M, et al. Linear accelerator radiosurgery for pituitary macroadenomas. A 7-year follow-up study. Cancer 2006, 107:1355-1364.
150. Chen CC, Chapman P, Petit J, Loeffler J Proton radiosurgery in neurosurgery. Neurosurg Focus 2007, 23:E5.
151. Petit JH, Biller BM, Coen JJ, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract 2007, 13:726-734.
152. Aghi MK, Petit J, Chapman P, et al. Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery. Clin Neurosurg 2008, 55:141-144.
153. Adler JR, Gibbs IC, Puataweepong P, Chang SD Visual field preservation after multisession Cyberknife radiosurgery for perioptic lesions. Neurosurgery 2006, 59:244-254.
154. Tuniz F, Soltys SG, Choi CY, et al. Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study. Neurosurgery 2009, 65:898-907.
155. Tsang RW, Brierley JD, Panzarella T, et al. Radiation therapy for pituitary adenoma. Treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys 1994, 30:557-565.
156. Becker G, Kocher M, Kortmann RD, et al. Radiation therapy in the multimodal treatment approach of pituitary adenomas. Strahlenther Onkol 2002, 178:173-186.
157. Erfurth EM, Bülow B, Svahn-Tapper G, et al. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 2002, 87:4892-4899.
158. Brada M, Burchell L, Ashley S, et al. The incidence of cerebrovascular accidents in patients with pituitary adenomas. Int J Radiat Oncol Biol Phys 1999, 45:693-698.
159. Lim YJ, Leem W, Park JT, et al. Cerebral infraction with ICA occlusion after Gamma Knife radiosurgery for pituitary adenoma. A case report. Stereotact Funct Neurosurg 1999, 72(Suppl 1):132-139.
160. Tooze A, Gittoes NJ, Jones CA, et al. Neurocognitive consequences of surgery and radiotherapy for tumours of the pituitary. Clin Endocrinol (Oxf) 2009, 70:503-511.
161. McCord MW, Buatti JM, Fennell EM, et al. Radiotherapy for pituitary adenomas. Long-term outcome and sequelae. Int J Radiat Oncol Biol Phys 1997, 39:437-444.
162. Noad R, Narayanan KR, Howlett T, et al. Evaluation of the effect of radiotherapy for pituitary tumours on cognitive function and quality of life. Clin Oncol (R Coll Radiol) 2004, 16:233-237.
163. Brada M, Ford D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. Br Med J 1992, 304:1343-1346.
164. Loeffler JS, Niemierko A, Chapman PH Second tumors after radiosurgery. Tip of the iceberg or a bump in the road?. Neurosurgery 2003, 52:1436-1440.
165. Rowe J, Grainger A, Walton L, et al. Risk for malignancy after gamma knife stereotactic radiosurgery. Neurosurgery 2007, 60:60-66.
166. Elston MS, McDonald KL, Clifton-Bligh RJ, Robinson BG Familial pituitary tumor syndromes. Nat Rev Endocrinol 2009, 5:453-461.
167. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas. A systematic review. Cancer 2004, 101:613-619.
168. Lloyd RJ, Kovacs K, Young WF, et al. Tumours of the pituitary gland. Pathology and genetics of tumours of endocrine organs 2004, 9-48. International Agency for Research and Cancer (IARC), Lyon, France. R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng (Eds.).
169. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome. An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:1526-1540.
170. Klibanski A Clinical practice. Prolactinomas. N Engl J Med 2010, 362:1219-1226.
171. Melmed S Medical progress. Acromegaly. N Engl J Med 2006, 355:2558-2573.
172. Ciric I, Ragin A, Baumgartner C, Pierce D Complications of transsphenoidal surgery. Results of the national survey, review of the literature, and personal experience. Neurosurgery 1997, 40:225-237.
173. Barker FG, Klibanski A, Swearingen B Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000. Mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003, 88:4709-4719.
174. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev 2010, 31:301-342.
175. Laws ER, Sheehan JP, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas. A review of the literature. J Neurooncol 2004, 69:257-272.
176. Minniti G, Gilbert DC, Brada M Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord 2009, 10:135-144.
177. Stafford SL, Pollock BE, Leavitt JA, et al. A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2003, 55:1177-1181.
178. Dekkers OM, Pereira AM, Roelfsema F, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006, 91:1796-1801.
179. Pollock BE, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas. Results from a 15-year experience. Int J Radiat Oncol Biol Phys 2008, 70:1325-1329.
180. Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993, 38:571-578.
181. Sasaki R, Murakami M, Okamoto Y, et al. The efficacy of conventional radiation therapy in the management of pituitary adenomas. Int J Radiat Oncol Biol Phys 2000, 47:1337-1345.
182. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev 2006, 27:485-534.
183. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994, 331:904-909.
184. Pouratian N, Sheehan J, Jagannathan J, et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 2006, 59:255-266.
185. Ježková J, Hána V, Kršek M, et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf) 2009, 70:732-741.
186. Castinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 2009, 94:3400-3407.
187. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management. An update. J Clin Endocrinol Metab 2009, 94:1509-1517.
188. Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010, 95:3141-3148.
189. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement. Medical management of acromegaly. Eur J Endocrinol 2005, 153:737-740.
190. Erturk E, Tuncel E, Kiyici S, et al. Outcome of surgery for acromegaly performed by different surgeons. Importance of surgical experience. Pituitary 2005, 8:93-97.
191. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342:1171-1177.
192. Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005, 62:210-216.
193. Jenkins PJ, Bates P, Carson MN, et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006, 91:1239-1245.
194. Pollock BE, Jacob JT, Brown PD, et al. Radiosurgery of growth hormone-producing pituitary adenomas. Factors associated with biochemical remission. J Neurosurg 2007, 106:833-838.
195. Jagannathan J, Pouratian N, Laws ER, et al. Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery. Neurosurgery 2008, 62:1262-1270.
196. Castinetti F, Morange I, Dufour H, et al. Radiotherapy and radiosurgery in acromegaly. Pituitary 2009, 12:3-10.
197. Landolt AM, Haller D, Lomax N, et al. Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metabol 2000, 85:1287-1289.
198. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome. A consensus statement. J Clin Endocrinol Metab 2008, 93:2454-2462.
199. Pouratian N, Prevedello DM, Jagannathan J, et al. Outcomes and management of patients with Cushing's disease without pathological confirmation of tumor resection after transsphenoidal surgery. J Clin Endocrinol Metab 2007, 92:3383-3388.
200. Patil CG, Prevedello DM, Lad SP, et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 2008, 93:358-362.
201. Schteingart DE Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs 2009, 14:661-671.
202. Minniti G, Osti M, Jaffrain-Rea ML, et al. Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neurooncol 2007, 84:79-84.
203. Höybye C, Grenbäck E, Rähn T, et al. Adrenocorticotropic hormone producing pituitary tumors:12-to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 2001, 49:284-292.
204. Mauermann WJ, Sheehan JP, Chernavvsky DR, et al. Gamma Knife surgery for adrenocorticotropic hormone-producing pituitary adenomas after bilateral adrenalectomy. J Neurosurg 2007, 106:988-993.
205. Pernicone PJ, Scheithauer BW, Sebo TJ, et al. Pituitary carcinoma. A clinicopathologic study of 15 cases. Cancer 1997, 79:804-812.
206. Schoenthaler R, Albright NA, Wara WM, et al. Re-irradiation of pituitary adenoma. Int J Radiat Oncol Biol Phys 1992, 24:307-314.
207. Sohn JW, Dalzell JG, Suh JH, et al. Dose-volume histogram analysis of techniques for irradiating pituitary adenomas. Int J Radiat Oncol Biol Phys 1995, 32:831-837.
208. Perks JR, Jalali R, Cosgrove VP, et al. Optimization of stereotactically guided conformal treatment planning of sellar and parasellar tumors, based on normal brain dose volume histograms. Int J Radiat Oncol Biol Phys 1999, 45:507-513.
209. Voges J, Kocher M, Runge M, et al. Linear accelerator radiosurgery for pituitary macroadenomas. A 7-year follow-up study. Cancer 2006, 107:1355-1364.
210. Petit JH, Biller BM, Coen JJ, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract 2007, 13:726-734.
211. Tuniz F, Soltys SG, Choi CY, et al. Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study. Neurosurgery 2009, 65:898-907.
212. Erfurth EM, Bülow B, Svahn-Tapper G, et al. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 2002, 87:4892-4899.
213. Brada M, Burchell L, Ashley S, et al. The incidence of cerebrovascular accidents in patients with pituitary adenomas. Int J Radiat Oncol Biol Phys 1999, 45:693-698.
214. Brada M, Ford D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. Br Med J 1992, 304:1343-1346.
215. Loeffler JS, Niemierko A, Chapman PH Second tumors after radiosurgery. Tip of the iceberg or a bump in the road?. Neurosurgery 2003, 52:1436-1440.
216. Rowe J, Grainger A, Walton L, et al. Risk for malignancy after gamma knife stereotactic radiosurgery. Neurosurgery 2007, 60:60-66.